These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31477437)

  • 1. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
    Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
    Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
    Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer.
    Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
    Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer.
    Lian T; Hao X; Li J; Wang H; Li C
    Med Oncol; 2020 Nov; 37(11):107. PubMed ID: 33136217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
    Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
    Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
    Palma M; Hansson L; Choudhury A; Näsman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widén K; Horváth R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
    Cancer Immunol Immunother; 2012 Jun; 61(6):865-79. PubMed ID: 22086161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.